Weight-Loss Drug Boom Threatens beer sales, Heineken warns UK pubs

Brewer advises smaller servings and low-alcohol options; industry opinions differ on long-term impact

By LineZotpaper

Published23 October 2026

Read Time2 min

Sources2 outlets

Heineken has warned British pubs and bars that the rising popularity of GLP-1 weight-loss drugs could lead to a drop in beer sales, as users reduce their alcohol consumption. In a presentation to hospitality customers, the world's second largest brewer advised venues to promote half pints, low and zero-alcohol drinks, and food pairings to counter potential declines in customer visits and spending.

Heineken, which also owns brands such as Amstel, Sol and Strongbow cider, shared the warning earlier this month in a presentation reported by Reuters. The document cautioned that the GLP-1 era could make the traditional multi-pint drinking session less frequent, citing trends among users toward smaller serves and lower alcohol options.

"We see some changes in consumption behaviour among (GLP-1) users and will continue to monitor how these behaviours evolve in 2027," the company told Reuters, noting that the presentation was part of regular engagement with UK businesses.

The potential impact of weight-loss drugs on alcohol consumption has drawn varying responses from other drinks firms. Diageo, the maker of Guinness, has told investors it views any disruption as manageable. Carlsberg, meanwhile, said it does not currently see data supporting a link between GLP-1 use and beer consumption trends.

Surveys by research firms Circana, NIQ and KAM have pointed to reduced drinking among GLP-1 users. Heineken highlighted that beer sales in British pubs, bars and restaurants totaled almost £14bn in the year to February, with less than £300m coming from no and low-alcohol products.

Use of GLP-1 medications such as Ozempic and Wegovy has surged, with 10 million people in the United States turning to the drugs last year, according to JP Morgan research.

Analysis

Why This Matters

The potential shift in drinking behavior due to GLP-1 drugs could have significant financial implications for the UK pub industry, which relies heavily on alcohol sales.
As weight-loss drug use grows globally, other beverage and food sectors may face similar disruptions.
The differing responses from major brewers indicate uncertainty about how quickly and deeply the trend will affect consumption patterns.

Background

GLP-1 receptor agonists, originally developed for diabetes, have gained widespread popularity as weight-loss aids. Drugs such as Ozempic and Wegovy suppress appetite and can reduce cravings, including for alcohol. With millions of users already in the US and rising adoption in Europe, businesses from food companies to brewers are assessing the potential knock-on effects on consumer behavior.

Key Perspectives

Heineken: The brewer is taking a proactive stance, advising hospitality clients to adapt their offerings to align with changing preferences for smaller portions and lower alcohol content.
Diageo: The Guinness owner has expressed confidence that any impact will be manageable, signaling a more cautious view on the scale of disruption.
Carlsberg: Currently sees no clear data supporting a link between weight-loss drugs and beer sales, suggesting that the trend may not yet be significant or may take longer to materialize.

What to Watch

Sales data for low and no-alcohol beer in UK pubs over the next year.
Prescription and usage rates of GLP-1 drugs in the UK and other key markets.
Whether other food and drink sectors report similar shifts in consumer spending.
Updating of earnings guidance from major brewers and beverage companies.

Sources

Boom in weight-loss drugs could lead to drop in beer sales, Heineken warns British pubs · Business | The Guardian
Boom in weight-loss drugs could lead to drop in beer sales, Heineken warns British pubs · World news | The Guardian

Checked

11 claims in this story checked against 1 source: 9 supported.

Show each claim

Partly supportedThe weight-loss drug boom threatens beer sales at UK pubs.Business | The Guardian: “Boom in weight-loss drugs could lead to drop in beer sales, Heineken warns British pubs.”
Partly supportedThe industry has differing views on the long-term impact of GLP-1 drugs.Business | The Guardian: “The Guinness maker, Diageo, has told investors that any impact from GLP-1 drugs becoming mainstream should be manageable, while Carlsberg told Reuters that data did not currently support the view that the use of weight-loss drugs affected beer consumption trends.”
SupportedHeineken warned that GLP-1 drug use could lead to lower beer sales as users drink less alcohol.Business | The Guardian: “Heineken has warned British bars and pubs that the boom in popularity of weight-loss drugs could lead to a fall in sales of beer and cider. The world’s second largest brewer sent a presentation to British hospitality customers earlier this month warning that GLP-1 use – led by Ozempic and Wegovy – can reduce the desire to drink alcohol”
SupportedHeineken advised venues to promote half pints, low- and zero-alcohol drinks, and food pairings to help counter possible declines in visits and spending.Business | The Guardian: “The Netherlands-headquartered company offered advice including promoting half pints, low- and zero-alcohol options and pairing drinks with small plates of food, or risk declines in customer visits and spending.”
SupportedThe presentation warned that multi-pint drinking sessions could become less frequent.Business | The Guardian: “The document, revealed by Reuters, warned that the GLP-1 era could lead to the tradition of the multi-pint drinking session becoming a less frequent occurrence.”
SupportedHeineken told Reuters: “We see some changes in consumption behaviour among (GLP-1) users and will continue to monitor how these behaviours evolve in 2027,”Business | The Guardian: ““We see some changes in consumption behaviour among (GLP-1) users and will continue to monitor how these behaviours evolve in 2027,” the company told Reuters.”
SupportedDiageo has told investors that any disruption from GLP-1 drugs becoming mainstream should be manageable.Business | The Guardian: “The Guinness maker, Diageo, has told investors that any impact from GLP-1 drugs becoming mainstream should be manageable”
SupportedCarlsberg said it does not currently see data supporting a link between GLP-1 use and beer consumption trends.Business | The Guardian: “Carlsberg told Reuters that data did not currently support the view that the use of weight-loss drugs affected beer consumption trends.”
SupportedSurveys by Circana, NIQ and KAM have pointed to reduced drinking among GLP-1 users.Business | The Guardian: “However, surveys by research companies including Circana, NIQ and KAM have pointed to reduced drinking by GLP-1 users.”
SupportedHeineken said beer sales in British pubs, bars and restaurants totalled almost £14bn in the year to February, with less than £300m from no- and low-alcohol products.Business | The Guardian: “According to Heineken, there was almost £14bn in sales of beer in British pubs, bars and restaurants in the year to February, with less than £300m of that from no- and low-alcohol products.”
Supported10 million people in the United States turned to GLP-1 medication last year, according to JP Morgan research.Business | The Guardian: “with 10 million people turning to medication in the US last year, according to research by JP Morgan.”